Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Osugacestat (AL101, BMS-906024)

ACCURACY

Ayala Pharmaceuticals · Phase 2 · Completed · Enrollment 87

NCT03691207

ArmPopulationDoseEstimandComparatorEfficacy
AL101 4 mgR/M ACC with NOTCH1 to 4 activating mutation (n = 45)4 mgSingle armn/rresponders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024median overall survival: 9.3 months, final
AL101 6 mgR/M ACC with NOTCH activating mutation (n = 42)6 mgSingle armn/rresponders (CR or PR): 2 patients (of 42), finalmedian overall survival: 9.4 months, final